Cargando…

Monomorphic Ventricular Tachycardia as a Presentation of Giant Cell Myocarditis

BACKGROUND: Idiopathic giant cell myocarditis (GCM) has a fulminant course and typically presents in middle-aged adults with acute heart failure or ventricular arrhythmia. It is a rare disorder which involves T lymphocyte-mediated myocardial inflammation. Diagnosis is challenging and requires a high...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Michael H., Trpkov, Cvetan, Rezazedeh, Saman, Chew, Derek S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607713/
https://www.ncbi.nlm.nih.gov/pubmed/31321103
http://dx.doi.org/10.1155/2019/7276516
_version_ 1783432132244275200
author Chiu, Michael H.
Trpkov, Cvetan
Rezazedeh, Saman
Chew, Derek S.
author_facet Chiu, Michael H.
Trpkov, Cvetan
Rezazedeh, Saman
Chew, Derek S.
author_sort Chiu, Michael H.
collection PubMed
description BACKGROUND: Idiopathic giant cell myocarditis (GCM) has a fulminant course and typically presents in middle-aged adults with acute heart failure or ventricular arrhythmia. It is a rare disorder which involves T lymphocyte-mediated myocardial inflammation. Diagnosis is challenging and requires a high index of suspicion since therapy may improve an otherwise uniformly fatal prognosis. CASE SUMMARY: A previously healthy 54-year-old female presented with hemodynamically significant ventricular arrhythmia (VA) and was found to have severe left ventricular dysfunction. Cardiac MRI demonstrated acute myocarditis, and endomyocardial biopsy showed giant cell myocarditis. She was treated with combined immunosuppressive therapy as well as guideline-directed medical therapy. A secondary prevention implantable cardioverter defibrillator (ICD) was implanted. DISCUSSION: GCM is a rare, lethal myocarditis subtype but is potentially treatable. Combined immunosuppression may achieve partial clinical remission in two-thirds of patients. VA is common, and patients should undergo ICD implantation. More research is needed to better understand this complex disease. LEARNING OBJECTIVES: Giant cell myocarditis is an incompletely understood, rare cause of myocarditis. Patients present predominately with heart failure and dysrhythmia. Diagnosis is confirmed by histopathology, and immunosuppression may improve outcomes. ICD implantation should be considered. In the absence of treatment, prognosis is poor with a median survival of three months.
format Online
Article
Text
id pubmed-6607713
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-66077132019-07-18 Monomorphic Ventricular Tachycardia as a Presentation of Giant Cell Myocarditis Chiu, Michael H. Trpkov, Cvetan Rezazedeh, Saman Chew, Derek S. Case Rep Cardiol Case Report BACKGROUND: Idiopathic giant cell myocarditis (GCM) has a fulminant course and typically presents in middle-aged adults with acute heart failure or ventricular arrhythmia. It is a rare disorder which involves T lymphocyte-mediated myocardial inflammation. Diagnosis is challenging and requires a high index of suspicion since therapy may improve an otherwise uniformly fatal prognosis. CASE SUMMARY: A previously healthy 54-year-old female presented with hemodynamically significant ventricular arrhythmia (VA) and was found to have severe left ventricular dysfunction. Cardiac MRI demonstrated acute myocarditis, and endomyocardial biopsy showed giant cell myocarditis. She was treated with combined immunosuppressive therapy as well as guideline-directed medical therapy. A secondary prevention implantable cardioverter defibrillator (ICD) was implanted. DISCUSSION: GCM is a rare, lethal myocarditis subtype but is potentially treatable. Combined immunosuppression may achieve partial clinical remission in two-thirds of patients. VA is common, and patients should undergo ICD implantation. More research is needed to better understand this complex disease. LEARNING OBJECTIVES: Giant cell myocarditis is an incompletely understood, rare cause of myocarditis. Patients present predominately with heart failure and dysrhythmia. Diagnosis is confirmed by histopathology, and immunosuppression may improve outcomes. ICD implantation should be considered. In the absence of treatment, prognosis is poor with a median survival of three months. Hindawi 2019-06-19 /pmc/articles/PMC6607713/ /pubmed/31321103 http://dx.doi.org/10.1155/2019/7276516 Text en Copyright © 2019 Michael H. Chiu et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Chiu, Michael H.
Trpkov, Cvetan
Rezazedeh, Saman
Chew, Derek S.
Monomorphic Ventricular Tachycardia as a Presentation of Giant Cell Myocarditis
title Monomorphic Ventricular Tachycardia as a Presentation of Giant Cell Myocarditis
title_full Monomorphic Ventricular Tachycardia as a Presentation of Giant Cell Myocarditis
title_fullStr Monomorphic Ventricular Tachycardia as a Presentation of Giant Cell Myocarditis
title_full_unstemmed Monomorphic Ventricular Tachycardia as a Presentation of Giant Cell Myocarditis
title_short Monomorphic Ventricular Tachycardia as a Presentation of Giant Cell Myocarditis
title_sort monomorphic ventricular tachycardia as a presentation of giant cell myocarditis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607713/
https://www.ncbi.nlm.nih.gov/pubmed/31321103
http://dx.doi.org/10.1155/2019/7276516
work_keys_str_mv AT chiumichaelh monomorphicventriculartachycardiaasapresentationofgiantcellmyocarditis
AT trpkovcvetan monomorphicventriculartachycardiaasapresentationofgiantcellmyocarditis
AT rezazedehsaman monomorphicventriculartachycardiaasapresentationofgiantcellmyocarditis
AT chewdereks monomorphicventriculartachycardiaasapresentationofgiantcellmyocarditis